News | FDA approves two new antibiotics to address global drug-resistant gonorrhea crisis
As gonorrhea infections continue to rise worldwide and antimicrobial resistance worsens, the U.S. Food and Drug Administration (FDA) recently approved the first new antibiotics for treating gonorrhea in decades. Public health experts believe this development could be a "critical turning point" in curbing the spread of drug-resistant gonorrhea.
Gonorrhea is one of the world's most common sexually transmitted infections, with more than 82 million cases each year. The burden is particularly high in Africa and the WHO Western Pacific Region, which spans a broad area from Mongolia and China to New Zealand. Cases are also rising rapidly in Europe: the infection rate in 2023 was three times that of 2014, while confirmed cases in England reached a record high.
Health agencies are highly concerned about the accelerating evolution of gonorrhea resistance. The World Health Organization has classified the causative bacterium, Neisseria gonorrhoeae, as a "priority pathogen." WHO surveillance data show that between 2022 and 2024, resistance to the current first-line treatment ceftriaxone rose from 0.8% to 5%, while resistance to cefixime increased from 1.7% to 11%.
Against this background, the new drug zoliflodacin (brand name Nuzolvence) received FDA approval on December 12 for treating gonorrhea. This oral medication is effective against some resistant strains. Tereza Kasaeva, Director of WHO's Department of Sexually Transmitted Infections, said: "With incidence rising globally, antimicrobial resistance increasing, and treatment options extremely limited, approval of new therapies is both important and timely."
Another antibiotic, gepotidacin, was developed by GSK and originally used to treat urinary tract infections. It was approved on December 11 to treat drug-resistant gonorrhea. This means U.S. regulators approved two entirely new treatment options within a single week, significantly expanding clinical choices.
The development pathway for zoliflodacin has also drawn attention. The drug emerged from a nonprofit-driven antibiotic development model led jointly by the Global Antibiotic Research and Development Partnership (GARDP) and pharmaceutical company Innoviva. GARDP Executive Director Manica Balasegaram said: "This approval marks a major turning point in treating multidrug-resistant gonorrhea. For too long, bacterial resistance has evolved faster than antibiotics have been developed."
Clinical trial results published in The Lancet showed that zoliflodacin cured more than 90% of genital gonorrhea infections. Its efficacy was comparable to the current standard treatment—an injection of ceftriaxone combined with oral azithromycin—and no serious safety concerns were observed. The study included 930 participants from Belgium, the Netherlands, South Africa, Thailand, and the United States, representing regional differences in resistance patterns.
Under the partnership agreement, GARDP holds registration and commercialization rights for the drug in all low-income countries, most middle-income countries, and some high-income countries, with the goal of ensuring access in high-burden regions.
Rossaphorn Kittiyaowamarn, the clinical trial lead in Thailand, said: "In clinical practice, we see every day the serious impact drug-resistant gonorrhea has on patients' lives. A single-dose oral treatment such as zoliflodacin will change the reality of gonorrhea prevention and control. It can reduce the burden on individuals and help stop highly resistant strains from spreading worldwide."
Public health experts broadly agree that approval of the new drugs does not mean the threat has passed. Precise, appropriate use of these antibiotics will be essential to delay the reemergence of resistance.
News | FDA Approves Two New Antibiotics to Address the Global Crisis of Drug-Resistant Gonorrhea
News | FDA approves two new antibiotics to address global drug-resistant gonorrhea crisis
As gonorrhea infections continue to rise worldwide and antimicrobial resistance worsens, the U.S. Food and Drug Administration (FDA) recently approved the first new antibiotics for treating gonorrhea in decades. Public health experts believe this development could be a "critical turning point" in curbing the spread of drug-resistant gonorrhea.
Gonorrhea is one of the world's most common sexually transmitted infections, with more than 82 million cases each year. The burden is particularly high in Africa and the WHO Western Pacific Region, which spans a broad area from Mongolia and China to New Zealand. Cases are also rising rapidly in Europe: the infection rate in 2023 was three times that of 2014, while confirmed cases in England reached a record high.
Health agencies are highly concerned about the accelerating evolution of gonorrhea resistance. The World Health Organization has classified the causative bacterium, Neisseria gonorrhoeae, as a "priority pathogen." WHO surveillance data show that between 2022 and 2024, resistance to the current first-line treatment ceftriaxone rose from 0.8% to 5%, while resistance to cefixime increased from 1.7% to 11%.
Against this background, the new drug zoliflodacin (brand name Nuzolvence) received FDA approval on December 12 for treating gonorrhea. This oral medication is effective against some resistant strains. Tereza Kasaeva, Director of WHO's Department of Sexually Transmitted Infections, said: "With incidence rising globally, antimicrobial resistance increasing, and treatment options extremely limited, approval of new therapies is both important and timely."
Another antibiotic, gepotidacin, was developed by GSK and originally used to treat urinary tract infections. It was approved on December 11 to treat drug-resistant gonorrhea. This means U.S. regulators approved two entirely new treatment options within a single week, significantly expanding clinical choices.
The development pathway for zoliflodacin has also drawn attention. The drug emerged from a nonprofit-driven antibiotic development model led jointly by the Global Antibiotic Research and Development Partnership (GARDP) and pharmaceutical company Innoviva. GARDP Executive Director Manica Balasegaram said: "This approval marks a major turning point in treating multidrug-resistant gonorrhea. For too long, bacterial resistance has evolved faster than antibiotics have been developed."
Clinical trial results published in The Lancet showed that zoliflodacin cured more than 90% of genital gonorrhea infections. Its efficacy was comparable to the current standard treatment—an injection of ceftriaxone combined with oral azithromycin—and no serious safety concerns were observed. The study included 930 participants from Belgium, the Netherlands, South Africa, Thailand, and the United States, representing regional differences in resistance patterns.
Under the partnership agreement, GARDP holds registration and commercialization rights for the drug in all low-income countries, most middle-income countries, and some high-income countries, with the goal of ensuring access in high-burden regions.
Rossaphorn Kittiyaowamarn, the clinical trial lead in Thailand, said: "In clinical practice, we see every day the serious impact drug-resistant gonorrhea has on patients' lives. A single-dose oral treatment such as zoliflodacin will change the reality of gonorrhea prevention and control. It can reduce the burden on individuals and help stop highly resistant strains from spreading worldwide."
Public health experts broadly agree that approval of the new drugs does not mean the threat has passed. Precise, appropriate use of these antibiotics will be essential to delay the reemergence of resistance.
Story source:
Collected online